-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Oncotelic Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Oncotelic Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.28M, a 22760% decline year-over-year.
- Oncotelic Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$3.62M, a 67.4% increase year-over-year.
- Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$6.65M, a 31.6% increase from 2022.
- Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$9.72M, a 6.53% decline from 2021.
- Oncotelic Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$9.13M, a 20.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)